Losartan potassium

Research use only, not for human use.

A selective, competitive angiotensin II receptor type 1 (AT1) antagonist (IC50=20 nM) for treatment of high blood pressure (hypertension).

A selective, competitive angiotensin II receptor type 1 (AT1) antagonist (IC50=20 nM) for treatment of high blood pressure (hypertension).Hypertension Approved(In Vitro):Losartan competes with the binding of angiotensin II to AT1 receptors. The concentration that inhibits 50% of the binding of angiotensin II (IC50) is 20 nM. Losartan (40 μM) affects ISC but prevents the effect of ANGII on ISC. Losartan significantly reduces Ang II-mediated cell proliferation in endometrial cancer cells. The combination of losartan and anti-miR-155 has a significantly greater antiproliferative effect compared to each drug alone.(In Vivo):Losartan (0.6 g/L, p.o.) -treated Fbn1C1039G/+ mice show a reduction in distal airspace caliber relative to placebo-treated Fbn1C1039G/+ animals. The doses of losartan and propranolol are titrated to achieve comparable hemodynamic effects. Analysis of pSmad2 nuclear staining reveals that losartan antagonizes TGF-β signaling in the aortic wall of Fbn1C1039G/+ mice. Losartan can improve disease manifestations in the lungs, an event that cannot plausibly relate to improved hemodynamics. Losartan (10 mg/kg, intraarterial injection) increases blood angiotensin levels four- to sixfold. Losartan (10 mg/kg, i.p.) increases plasma renin levels 100-fold; plasma angiotensinogen levels decreases to 24% of control; and plasma aldosterone levels are unchanged.

——

——

DuP-753 potassium

GPCR/G Protein

Angiotensin Receptor

AT1receptor

Cardiovascular Disease

Hypertension

124750-99-8

461.001

C22H22ClKN6O

>98% (HPLC)

10 mM in DMSO

[K].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=N[N-]1

1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, potassium salt (1:1)

(-20℃)

With Ice Pack

≥ 2 years